Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

Nagaraja M. Phani; Manik Vohra; Ananth Kakar; Prabha Adhikari; Shivashankara K. Nagri; Sydney C. D'Souza; Shashikiran Umakanth; Kapaettu Satyamoorthy; Padmalatha S. Rai

doi:10.2217/pgs-2018-0041

Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

Nagaraja M. Phani
, Manik Vohra
, Ananth Kakar
, Prabha Adhikari
, Shivashankara K. Nagri
, Sydney C. D'Souza
, Shashikiran Umakanth
, Kapaettu Satyamoorthy
, Padmalatha S. Rai^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

Original language	English
Pages (from-to)	905-911
Number of pages	7
Journal	Pharmacogenomics
Volume	19
Issue number	11
DOIs	https://doi.org/10.2217/pgs-2018-0041
Publication status	Published - 01-01-2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2018-0041

Cite this

@article{8dfe705659a44d4188227d3ee35ef051,

title = "Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes",

abstract = "Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.",

author = "Phani, \{Nagaraja M.\} and Manik Vohra and Ananth Kakar and Prabha Adhikari and Nagri, \{Shivashankara K.\} and D'Souza, \{Sydney C.\} and Shashikiran Umakanth and Kapaettu Satyamoorthy and Rai, \{Padmalatha S.\}",

note = "Publisher Copyright: {\textcopyright} 2018 2018 Future Medicine Ltd.",

year = "2018",

month = jan,

day = "1",

doi = "10.2217/pgs-2018-0041",

language = "English",

volume = "19",

pages = "905--911",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

AU - Phani, Nagaraja M.

AU - Vohra, Manik

AU - Kakar, Ananth

AU - Adhikari, Prabha

AU - Nagri, Shivashankara K.

AU - D'Souza, Sydney C.

AU - Umakanth, Shashikiran

AU - Satyamoorthy, Kapaettu

AU - Rai, Padmalatha S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

AB - Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

UR - https://www.scopus.com/pages/publications/85049916591

UR - https://www.scopus.com/pages/publications/85049916591#tab=citedBy

U2 - 10.2217/pgs-2018-0041

DO - 10.2217/pgs-2018-0041

M3 - Article

AN - SCOPUS:85049916591

SN - 1462-2416

VL - 19

SP - 905

EP - 911

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 11

ER -

Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this